Drugs / Vivotif

Trials 5 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03312699 Sep 2017 → Dec 2023 hepatitis A virus infection, influenza, typhoid fever Stanford University Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00751933 Oct 2008 → Oct 2009 ulcerative colitis Haukeland University Hospital Terminated No outcome recorded
Phase 43 trials
Phase 4 NCT06104345 Oct 2023 → Jun 2024 cholera, typhoid fever Helsinki University Central Hospital Completed No outcome recorded
Phase 4 NCT03705585 Nov 2018 → May 2029 expected University of Maryland, Baltimore Recruiting No outcome recorded
Phase 4 NCT02121145 Oct 2013 → Dec 2019 Helsinki University Central Hospital Unknown No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT03971669 Background Jan 2004 → Jun 2030 expected University of Maryland, Baltimore Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Vivotif “Oral typhoid fever vaccine (Vivotif®) on Days 0, 2 and 4.” NCT06104345
5

NCT03312699

NCT03971669

NCT03705585

NCT02121145

NCT00751933

Modality Vaccine Vaccine Vivotif + Vaccine Dukoral + oats” NCT00751933
Route Oral “One capsule is to be swallowed approximately 1 hour before a meal” NCT03312699